Biologics in combination with nonbiologics: Efficacy and safety

Dermatologic Therapy

Volumn 17, Issue 5, 2004, Pages 432-440

  Stebbins, William G ^a   Lebwohl, Mark G ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Biologics; Combination therapy; Psoriasis

Indexed keywords

ADALIMUMAB; ALEFACEPT; ANTIPSORIASIS AGENT; CORTICOSTEROID; CYCLOSPORIN A; EFALIZUMAB; ETANERCEPT; ETRETIN; IMMUNOLOGIC AGENT; INFLIXIMAB; METHOTREXATE; NEUTRALIZING ANTIBODY;

ACCURACY; ASPERGILLOSIS; B CELL LYMPHOMA; CANDIDIASIS; CLINICAL TRIAL; CROHN DISEASE; DOSE RESPONSE; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG SAFETY; HISTOPLASMOSIS; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION; INFECTION RISK; LIVER TOXICITY; LONG TERM CARE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; PHARYNGITIS; PHOTOTHERAPY; PSORIASIS; PSORIASIS VULGARIS; QUANTITATIVE ANALYSIS; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SIDE EFFECT; SINUSITIS; SKIN MANIFESTATION; T LYMPHOCYTE ACTIVATION; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; PSORIASIS;

EID: 6344231980     PISSN: 13960296     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1396-0296.2004.04046.x     Document Type: Review

References (65)

1. Bjerke JR, Krogh HK, Matre R. Characterization of mononuclear cell infiltrates in psoriatic lesions. J Invest Dermatol 1978: 71: 340-343.
2. Snowden JA, Heaton DC. Development of psoriasis after syngeneic bone marrow transplant from psoriatic donor: further evidence for adoptive autoimmunity. Br J Dermatol 1997: 137: 130-132.
3. Lebwohl M. Psoriasis. Lancet 2003: 361: 1197-1204.
4. Yamauchi PS, Rizk D, Kormeili T, Patnaik R, Lowe NJ. Current systemic therapies for psoriasis. Where are we now? J Am Acad Dermatol 2003: 49: S66-S77.
5. Gommans JM, van Hezik SJ, van Huystee BE. Flow cytometric quantification of T6-positive cells in psoriatic epidermis after PUVA and methotrexate therapy. Br J Dermatol 1987: 116: 661-666.
6. Newton JA, Camplejohn RS, Bowyer C, McGibbon DH, Wright NA. Study of psoriatic epidermal cell kinetics and cell death after oral methotrexate. Dermatologica 1985: 171: 469-473.
7. Roenigk HH Jr, Auerbach R, Maibach H, Weinstein G, Lebwohl M. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998: 38: 478-485.
8. Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. J Am Acad Dermatol 1993: 28: 466-469.
9. Hoekstra M, van Ede AE, Haagsma CJ, et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 2003: 62: 423-426.
10. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991: 90: 711-716.
11. Lebwohl M, Ellis C, Gottlieb A, et al. Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Am Acad Dermatol 1998: 39: 464-475.
12. Zachariae H, Kragballe K, Hansen HE, Marcussen N, Olsen S. Renal biopsy findings in long-term cyclosporin treatment of psoriasis. Br J Dermatol 1997: 136: 531-535.
13. Lowe NJ, Wieder JM, Rosenbach A, et al. Long-term, low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure. J Am Acad Dermatol 1996: 35: 710-719.
14. Clark CM, Kirby B, Morris AD, et al. Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis. Br J Dermatol 1999: 141: 279-282.
15. Stack WA, Richardson PD, Logan RP, Mahida YR, Hawkey CJ. Nocardia asteroides lung abscess in acute ulcerative colitis treated with cyclosporine. Am J Gastroenterol 2001: 96: 2255-2256.
16. Cainelli F, Concia E, Vento S. Cryptococcal meningitis during cyclosporin treatment in a patient with psoriasis. Br J Dermatol 2000: 143: 1327-1328.
17. Srivastava T, Zwick DL, Rothberg PG, Warady BA. Posttransplant lymphoproliferative disorder in pediatric renal transplantation. Pediatr Nephrol 1999: 13: 748-754.
18. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999: 397: 530-534.
19. Korstanje MJ, Hulsmans RF. Combination therapy cyclosporin A - PUVA in psoriasis. Acta Derm Venereol 1990: 70: 89-90.
20. Lebwohl M. Acitretin in combination with UVB or PUVA. J Am Acad Dermatol 1999: 41: S22-S24.
21. Iest J, Boer J. Combined treatment of psoriasis with acitretin and UVB phototherapy compared with acitretin alone and UVB alone. Br J Dermatol 1989: 120: 665-670.
22. Lowe NJ, Prystowsky JH, Bourget T, Edelstein J, Nychay S, Armstrong R. Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol 1991: 24: 591-594.
23. Lebwohl M, Drake L, Menter A, et al. Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis. J Am Acad Dermatol 2001: 45: 544-553.
24. Bavinck JN, Tieben LM, Van der Woude FJ, et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol 1995: 13: 1933-1938.
25. Gibson GE, O'Grady A, Kay EW, Murphy GM. Low-dose retinoid therapy for chemoprophylaxis of skin cancer in renal transplant recipients. J Eur Acad Dermatol Venereol 1998: 10: 42-47.
26. Kelly JW, Sabto J, Gurr FW, Bruce F. Retinoids to prevent skin cancer in organ transplant recipients. Lancet 1991: 338: 1407.
27. Lebwohl M, Tannis C, Carrasco D. Acitretin suppression of squamous cell carcinoma: case report and literature review. J Dermatolog Treat 2003: 14 (Suppl. 2): 3-6.
28. Foundation NP. The research pipeline for psoriasis. The Bulletin 2000: 31: 8-9.
29. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 2000: 356: 385-390.
30. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999: 130: 478-486.
31. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998: 41: 1552-1563.
32. Maini RN, Taylor PC, Paleolog E, et al. Anti-tumor necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis. Ann Rheum Dis 1999: 58 (Suppl. 1): I56-I60.
33. Cursiefen C, Holbach LM. Molluscum contagiosum in immunosuppression with methotrexate: multiple warts with central depressions of the eyelids. Klin Monatsbl Augenheilkd 1998: 212: 123-124.
34. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 2000: 343: 1594-1602.
35. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001: 345: 1098-1104.
36. Lim WS, Powell RJ, Johnston ID. Tuberculosis and treatment with infliximab. N Engl J Med 2002: 346: 623-626.
37. Myers A, Clark J, Foster H. Tuberculosis and treatment with infliximab. N Engl J Med 2002: 346: 623-626.
38. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001: 344: 1099-1100.
39. Zhang Z, Correa H, Begue RE. Tuberculosis and treatment with infliximab. N Engl J Med 2002: 346: 623-626.
40. Schwartz JJ, Myskowski PL. Molluscum contagiosum in patients with human immunodeficiency virus infection. A review of 27 patients. J Am Acad Dermatol 1992: 27: 583-588.
41. Bresnihan B, Cunnane G. Infection complications associated with the use of biologic agents. Rheum Dis Clin North Am 2003: 29: 185-202.
42. Fratazzi C, Arbeit RD, Carini C, Remold HG. Programmed cell death of Mycobacterium avium serovar 4-infected human macrophages prevents the mycobacteria from spreading and induces mycobacterial growth inhibition by freshly added, uninfected macrophages. J Immunol 1997: 158: 4320-4327.
43. Garcia I, Miyazaki Y, Marchal G, Lesslauer W, Vassalli P. High sensitivity of transgenic mice expressing soluble TNFR1 fusion protein to mycobacterial infections: synergistic action of TNF and IFN-gamma in the differentiation of protective granulomas. Eur J Immunol 1997: 27: 3182-3190.
44. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999: 340: 1398-1405.
45. Helbling D, Breitbach TH, Krause M. Disseminated cytomegalovirus infection in Crohn's disease following anti-tumor necrosis factor therapy. Eur J Gastroenterol Hepatol 2002: 14: 1393-1395.
46. Cockburn IT, Krupp P. The risk of neoplasms in patients treated with cyclosporine A. J Autoimmun 1989: 2: 723-731.
47. Penn I. Cancers following cyclosporine therapy. Transplantation 1987: 43: 32-35.
48. Iyer S, Yamauchi P, Lowe NJ. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol 2002: 146: 118-121.
49. Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003: 48: 319-324.
50. Cohen RB, Dittrich KA. Anti-TNF therapy and malignancy - a critical review. Can J Gastroenterol 2001: 15: 376-384.
51. Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud N, Sibilia J. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002: 99: 3909-3915.
52. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999: 5: 119-133.
53. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: 26 cases reported to the Food and Drug Administration. Arthritis Rheum 2002: 46: 3151-3158.
54. Gottlieb A, Vaishnaw A, Gordon K. Immune response to neo-recalled antigens is not altered by alefacept. 60th Annual Meeting of the Americal Academy of Dermatology. New Orleans, LA: 2002.
55. Krueger G, Rizova E. Duration of response to alefacept therapy in patients with chronic plaque psoriasis. 60th Annual Meeting of the American Academy of Dermatology. New Orleans, LA: 2002.
56. Krueger J, Gottlieb A, Miller B, Dedrick R, Garovoy M, Walicke P. Anti-CD11a treatment for psoriasis concurrently increases circulating T cells and decreases plaque T cells, consistent with the inhibition of cutaneous T cell trafficking. J Invest Dermatol 2000: 115: 333.
57. Gottlieb A, Krueger JG, Bright R, et al. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 2000: 42: 428-435.
58. Nuijten MJ, Engelfriet P, Duijn K, Bruijn G, Wierz D, Koopmanschap M. A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. Pharmacoeconomics 2001: 19: 1051-1064.
59. Choi HK, Seeger JD, Kuntz KM. A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis Rheum 2000: 43: 2316-2327.
60. Shergy WJ, Isern RA, Cooley DA, et al. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. J Rheumatol 2002: 29: 667-677.
61. Cursiefen C, Grunke M, Dechant C, Antoni C, Junemann A, Holbach LM. Multiple bilateral eyelid molluscum contagiosum lesions associated with TNF-alpha-antibody and methotrexate therapy. Am J Ophthalmol 2002: 134: 270-271.
62. Matzkies FG, Manger B, Schmitt-Haendle M, et al. Severe septicemia in a patient with polychondritis and Sweet's syndrome after initiation of treatment with infliximab. Ann Rheum Dis 2003: 62: 81-82.
63. Mahe E, Descamps V, Grossin M, Fraitag S, Crickx B. CD30+ T cell lymphoma in a patient with psoriasis treated with cyclosporin and infliximab. Br J Dermatol 2003: 149: 170-173.
64. Lim IG, Bertouch JV. Remission of lymphoma after drug withdrawal in rheumatoid arthritis. Med J Aust 2002: 177: 500-501.
65. Baird RD, Van Zyl-Smit RN, Dilke T, Scott SE, Rassam SM. Spontaneous remission of low-grade B-cell non-Hodgkin's lymphoma following withdrawal of methotrexate in a patient with rheumatoid arthritis: case report and review of the literature. Br J Haematol 2002: 118: 567-568.